No profile data available.
NeuroSense Therapeutics Ltd. (NRSN) is a healthcare company in the brain and nerve treatment drugs industry, based in Herzliya, Israel, with about 17 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$11.13 million. Its market capitalization was $6.94 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally.
NeuroSense Therapeutics reported $0 in revenue for fiscal year 2025.
$6.94 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Vistagen Therapeutics, Inc. (VTGN), Aeon Biopharma, Inc. (AEON), NKGen Biotech, Inc. (NKGN), Brainstorm Cell Therapeutics Inc. (BCLI).